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Introduction
Patients with chronic kidney disease (CKD) are predisposed to
heart rhythm disorders, including atrial fibrillation (AF)/atrial
flutter, supraventricular tachycardias, ventricular arrhythmias, and
sudden cardiac death (SCD). While treatment options, including
drug, device, and procedural therapies, are available, their use in
the setting of CKD is complex and limited. Patients with CKD
and end-stage kidney disease (ESKD) have historically been
under-represented or excluded from randomized trials of
arrhythmia treatment strategies,1 although this situation is
changing.2 Cardiovascular society consensus documents have
recently identified evidence gaps for treating patients with CKD
and heart rhythm disorders.3–7
To identify key issues relevant to the optimal prevention, manage-
ment, and treatment of arrhythmias and their complications in pa-
tients with kidney disease, Kidney Disease: Improving Global
Outcomes (KDIGO) convened an international, multidisciplinary
Controversies Conference in Berlin, Germany, titled CKD and
Arrhythmias in October 2016. The conference agenda and discussion
questions are available on the KDIGO website (http://kdigo.org/con
ferences/ckd-arrhythmias/; 13 February 2018).
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Atrial fibrillation and stroke in
kidney disease
Epidemiology
Atrial fibrillation is the most common sustained arrhythmia.8 Chronic
kidney disease affects 10% of adults worldwide,9 and patients with
CKD have an increased burden of AF compared with those without
CKD (Supplementary material online, Table S1). The prevalence of
AF is high: estimates range from 16% to 21% in CKD patients not de-
pendent on dialysis10–12 and 15% to 40% in patients on dialysis
(Supplementary material online, Table S1).13–18 Chronic kidney dis-
ease and AF share many risk factors, making it difficult to discern the
contributions of individual factors to either condition or associated
outcomes (Figure 1). For non-dialysis CKD, there seems to be an
independent relationship between CKD and the risk of AF,19–25
although this association has not been well characterized across the
spectrum of estimated glomerular filtration rate (eGFR) or protein-
uria.13,14,26,27 In the USA, both incidence and prevalence of AF are
increasing among haemodialysis patients,27,28 which could be because
of older age of patients, better ascertainment of AF, and improved
survival after vascular events.
Consequences of atrial fibrillation in
chronic kidney disease
The risk of stroke is elevated in non-dialysis29–32 and dialysis29,31,33
CKD (Supplementary material online, Table S2). Separately, both
CKD and AF are risk factors for stroke, but it is currently unknown
whether the prognostic significance of CKD markers and AF is inde-
pendent or interdependent. The association between AF and CKD
may be bidirectional; AF may predict new-onset low GFR and pro-
teinuria.21 In CKD, the adjusted risk ratios of stroke with AF have var-
ied considerably across CKD subpopulations, ranging from 4.2 in
women in the general population,34 1.3 in dialysis patients,33,35 and
with modestly significant (1.4)36 and non-significant37 associations
after kidney transplantation. These differences may be due to greater
competing risk of death in more advanced CKD,35 a higher baseline
risk of stroke in CKD without AF, or a higher prevalence of unrecog-
nized AF.
AF increases the risk of incident CKD and progression to
ESKD21,38–40 (Supplementary material online, Table S3), and increases
risk of death in patients with non-dialysis CKD and those on dialy-
sis.13,35,41,42 Other outcomes related to AF, including heart failure,
SCD, and myocardial infarction (MI), require further research. The
contribution of AF as a mediator of stroke in CKD, as well as the
stroke subtypes observed, requires further study. The competing risk
of death in CKD may reduce the importance of the contribution of
AF to stroke, which could mitigate the effectiveness of some stroke
prevention strategies.35
Stroke risk scores
The predictive value and calibration of the CHADS2 and CHA2DS2-
VASc stroke prediction scores have only been evaluated in dialysis
patients, in which performance appears to be similar to their per-
formance in the general population.16,33,43,44
Inclusion of CKD in risk scores to improve stroke prediction
has demonstrated variable results. Adding two points for creatinine
clearance < 60 mL/min to CHADS2 (called R2CHADS2) improved
net reclassification index (NRI) but not C-statistic in one large study
using external validation30 but did not improve NRI or C-statistic in
other studies.45,46 The ATRIA score, which includes terms for
GFR < 45 mL/min/1.73 m2 and proteinuria, demonstrated improved
NRI and borderline improvement in C-statistic compared with
CHADS2 and CHA2DS2-VASc in external validation,
47 although NRI
may not be clinically meaningful.48 For these reasons and for the po-
tential for categorically recommending oral anticoagulant (OAC) to
most patients with CKD without regard to competing risks,
CHA2DS2-VASc remains the most commonly recommended score
for risk stratification,5,49 and observational data have shown that a
treatment threshold of CHA2DS2-VASc >_ 2 is associated with OAC
benefit, even in CKD.50
Bleeding risk scores
The HAS-BLED, ORBIT, HEMORR2HAGES, and ATRIA bleeding
risk scores all include CKD measures. Although the formal use of
these bleeding risk scores has not been recommended by the major-
ity of professional society guidelines,49,51 the increased risk of bleed-
ing with and without OAC in CKD is well described and should be
considered in clinical decision making.
Stroke prevention and oral
anticoagulation
The pathophysiologic mechanisms responsible for stroke/thrombo-
embolism in patients with CKD and AF are multifactorial and poorly
Figure 1 Relationship between chronic kidney disease and atrial
fibrillation: shared risk factors and outcomes. Chronic kidney dis-
ease and atrial fibrillation share a number of risk factors and condi-
tions that promote their incidence, possibly via systemic processes
such as inflammation, oxidative stress, or fibrosis. It is established
that chronic kidney disease increases the incidence of atrial fibrilla-
tion and there is some evidence to suggest that atrial fibrillation also
increases chronic kidney disease progression. When examining the
strength of these associations, we acknowledge the potential impact
of detection bias in observational studies where more frequent ex-
posure to healthcare likely prompts more clinical findings in this
comorbid population. AF, atrial fibrillation; CKD, chronic kidney dis-
ease; CVD, cardiovascular disease.
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understood; the precise contribution of cardio-embolic vs. non-
cardioembolic factors is unclear. Atrial fibrillation may be a direct
cause of cardio-embolic stroke, a risk marker of ischaemic stroke
including atherothrombotic subtypes, and in rare cases, a conse-
quence of stroke.52
Chronic kidney disease patients with
estimated creatinine clearance of
30–50 mL/min
Pivotal randomized controlled trials (RCTs) have established that dir-
ect oral anticoagulants (DOACs) are non-inferior to warfarin among
patients with Cockroft–Gault estimated creatinine clearance (eCrCl)
of 30–50 mL/min (for apixaban, 25–50 mL/min).53–56 However, there
is insufficient evidence to recommend any one DOAC over any
other in this population because no head-to-head trials have directly
compared individual DOACs57–62 (Table 1). Indirect comparisons are
challenging because these trials differed in inclusion criteria and out-
come definitions.
Although efficacy (prevention of stroke and systemic embolism)
may merely be non-inferior to warfarin, the safety profile of DOACs
compared to warfarin does appear to be superior. In all pivotal RCTs,
DOACs have been associated with a significant reduction (about
50%) in risk of intracranial haemorrhage compared to warfarin.
Among patients with eCrCl between 25 and 50 mL/min, treatment
with apixaban and edoxaban resulted in significantly fewer major
bleeding events compared with warfarin (Figure 2).63 Although these
observations do not necessarily indicate the superiority of apixaban
and edoxaban relative to other DOACs, it may be helpful to clinicians
when treating patients at particularly high-bleeding risk or low time in
therapeutic range (TTR) values while receiving warfarin or other vita-
min K antagonists (VKAs).
Chronic kidney disease G4, G5, and G5D
In the absence of trial data, the results from observational studies on
the efficacy and safety of anticoagulation for stroke prevention in
CKD patients with eCrCl < 30 mL/min not on dialysis are conflicting
as they are for CKD G5D (Table 2).65 There is insufficient high-
quality evidence to recommend warfarin or other VKAs for preven-
tion of stroke in CKD G5D patients with AF, especially when
balancing the significant risks of bleeding, accelerated vascular calcifi-
cation, and calcific uraemic arteriopathy associated with VKA ther-
apy.66 A pooled meta-analysis of 56 146 CKD G5D patients with AF
from 20 observational cohort studies demonstrated an increase in
all-cause bleeding associated with VKA therapy without benefit in re-
duction of all-cause stroke or ischaemic stroke.65 Yet, a well-
conducted observational analysis of acute MI patients with AF from
the SWEDEHEART registry (2003–2010) found that VKA therapy
was associated with a reduced risk of a composite of death, MI, and is-
chaemic stroke with no increase in bleeding risk across the spectrum
of CKD.67 The high time in international normalized ratio (INR) TTR
in Sweden (>75%) likely contributed to these findings and has been
difficult to replicate in other health systems.68 A large US health care
system analysis found that CKD severity is associated with decreased
TTR despite similar INR monitoring intensity.69 These findings sug-
gest that TTR is more likely to be poor in CKD and can mediate the
increased stroke and bleeding risk in CKD.70 VKAs may lead to CKD
via repeated subclinical glomerular haemorrhages71 or through accel-
erated tissue or vascular calcification.72
The US Food and Drug Administration recently approved mention
of the doses of apixaban 5 mg twice daily (with contingent dose modifi-
cations) and rivaroxaban 15 mg daily in CKD G5 and G5D (and dabiga-
tran 75 mg orally twice daily for eCrCl 15–30 mL/min) on the
respective labels based on single/limited dose pharmacokinetic and
pharmacodynamic data with no clinical safety data.73–76 The conference
attendees suggest consideration of the lower dose of apixaban 2.5 mg
orally twice daily in CKD G5/G5D to reduce bleeding risk until clinical
safety data are available, an approach supported by a recent pharmaco-
kinetic study comparing the two doses.77 Recognizing that many CKD
patients would likely qualify for a dose reduction to apixaban 2.5 mg or-
ally twice daily anyway (if age >_80 years or body weight <_ 60 kg), this
suggestion honours the ‘first do no harm’ principle, while acknowledg-
ing the lack of clinical efficacy or safety data in this regard (Table 2).
Randomized clinical trials are particularly needed to evaluate VKA
use in patients with CKD G5D. A clinical trial evaluating VKAs vs. no
oral anticoagulation (AVKDIAL, NCT02886962) is planned. It is not
known whether DOACs have an advantage over VKAs in CKD G5D
patients with AF. The AXADIA (NCT02933697) and RENAL-AF
(NCT02942407) trials of apixaban vs. VKAs in ESKD are enrolling in
Germany and USA.
....................................................................................................................................................................................................................
Table 1 Evidence from randomized trial data regarding therapeutic anticoagulation on the basis of kidney
function4,63,64
eCrCl (mL/min)a Warfarin Apixabanb Dabigatran Edoxabanc Rivaroxaban
>95 Adjusted dose (INR 2–3) 5mg b.i.d. 150mg b.i.d. 60mg QDd 20mg QD
51–95 Adjusted dose (INR 2–3) 5mg b.i.d. 150mg b.i.d. 60mg QD 20mg QD
31–50 Adjusted dose (INR 2–3) 5mg b.i.d.(eCrCl cut-off25mL/min) 150mg b.i.d. or 110mg b.i.d.e 30mg QD 15mg QD
INR, international normalized ratio.
aCockcroft-Gault estimated creatinine clearance (eCrCl).
bApixaban dose modification from 5mg b.i.d. to 2.5mg b.i.d. if patient has any two of the following: serum creatinine >_1.5mg/dL, age >_80years, or body weight <_60kg.
cIn the ENGAGE-AF TIMI 48 study, the dose was halved if any of the following: eCrCl of 30–50mL/min, body weight <_60kg, or concomitant use of verapamil or quinidine (po-
tent P-glycoprotein inhibitors).
dThis dose has not been approved for use by the US Food and Drug Administration in this category of kidney function.
eIn countries where 110 mg b.i.d. is approved, clinicians may prefer this dose after clinical assessment of thromboembolic vs bleeding risk. This dose has not been approved for
use by the US Food and Drug Administration.
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.Pragmatic considerations while
managing anticoagulation in chronic
kidney disease
In pivotal RCTs, study eligibility and DOAC dose assignments were
based on kidney function as assessed using eCrCl (Cockcroft-Gault).
However, in clinical practice, other measures such as eGFR are rou-
tinely used. Given the imprecision in measures for estimating kidney
function, individualization of DOAC dosing based on either method
is reasonable.78–80 Important safety concerns, mainly increased fatal
or non-fatal bleeding, emerged after the early ‘off-label’ prescriptions
of dabigatran and rivaroxaban in patients with CKD G5D.81–83
A recent study of 1473 AF patients with renal indication for dose
reduction found that 43% were potentially overdosed with DOACs,
resulting in higher bleeding risk.84 These adverse signals suggest the
Figure 2 Efficacy and safety of direct oral anticoagulants (DOACs) vs. warfarin in the subgroup of patients with moderate chronic kidney disease
from randomized controlled trials in atrial fibrillation. Comparison of hazard ratios and 95% confidence intervals for primary efficacy and safety
outcomes for 150 and 110 mg dabigatran twice daily, 15 mg rivaroxaban once daily, 5 mg apixaban twice daily, and 30 mg edoxaban once daily.
Chronic kidney disease was defined as estimated creatinine clearance of 30 to 49 mL/min or as 25 to 49 mL/min for apixaban. aApixaban 2.5 mg twice
daily if patient had any two of the following: age >_ 80 years, body weight <_ 60 kg, or serum creatinine >_1.5 mg/dL. Reproduced from Qamar and
Bhatt63 with permission from the publisher.
....................................................................................................................................................................................................................
Table 2 Chronic kidney disease categories lacking randomized clinical trial data on the utility of anticoagulation4,63,64
eCrCl (mL/min)a Warfarin Apixabanb Dabigatran Edoxaban Rivaroxaban
15–30 Adjusted dose for INR
2–3 could be
considered
2.5mg PO b.i.d. could
be considered
Unknown (75mg PO
b.i.d.)c,d
30mg QDe could be
considered
15mg QD could be
considered
<15 not on dialysis Equipoise based on
observational data
and meta-analysis
Unknown (2.5mg PO
b.i.d.)c
Not recommended Not recommended Unknown (15mg
QD)c
<15 on dialysis Equipoise based on
observational data
and meta-analysis
Unknown (2.5mg PO
b.i.d.)c
Not recommended Not recommended Unknown (15mg
QD)c
INR, international normalized ratio.
Dosing of direct oral anticoagulants (DOACs) based solely on limited pharmacokinetic and pharmacodynamic data (no randomized efficacy or safety data exist).
aCockcroft-Gault estimated creatinine clearance.
bApixaban dose needs modification to 2.5mg b.i.d. if patient has any two of the following: serum creatinine >_1.5mg/dL, age >_80years, or body weight <_60kg.
cDOAC doses listed in parenthesis are doses that do not currently have any clinical safety or efficacy data. The doses of DOACs apixaban 5mg b.i.d.b, rivaroxaban 15mg QD
and dabigatran 75mg b.i.d. are included in the United States Food and Drug Administration approved labelling based on limited dose pharmacokinetic and pharmacodynamics
data with no clinical safety data. We suggest consideration of the lower dose of apixaban 2.5mg PO b.i.d. in CKD G5/G5D to reduce bleeding risk until clinical safety data are
available.
dDabigatran 75mg available only in the USA.
eThe dose was halved if any of the following: estimated CrCl of 30–50mL/min, body weight of <_60kg, or concomitant use of verapamil or quinidine (potent P-glycoprotein
inhibitors).
4 M.P. Turakhia et al.
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.need for systemic measures focused on patient safety to guide clin-
icians regarding the use of DOACs.85
Team-based, multidisciplinary active communication, particularly
involving the nephrologist, cardiologist (or cardiac electrophysiolo-
gist), primary care physician, and when possible, clinical pharmacist,
may be useful to evaluate the risk–benefit of any decision regarding
choice of VKA or a DOAC.5,85
For CKD patients receiving DOAC therapy, we recommend peri-
odic monitoring of kidney function because decline over time may ne-
cessitate dose modification.86 There are no data to indicate the
optimal frequency of monitoring, but it may be clinically reasonable to
assess kidney function every 6 to 12 months, (or at least yearly, consist-
ent with professional society guidelines),5 with more or less frequent
monitoring as appropriate based on recency of DOAC initiation, CKD
severity, and CKD trajectory. For all CKD patients on anticoagulant
therapy, annual re-evaluation of treatment goals and discussion of pros
and cons of anticoagulant therapy should be considered.
Periprocedural/perioperative management of DOACs is contingent
upon individual agents and eCrCl, for which recommended param-
eters exist (Table 3).4,87 For patients with CKD G5D on anticoagulants,
strategies to reduce bleeding warrant systematic research but may in-
clude minimizing heparin with dialysis, use of citrate locks for cath-
eters,88 consideration of prophylaxis for gastrointestinal bleeding
when clinically indicated, tight blood pressure control, and discontinu-
ation of concurrent antiplatelet agents if clinically reasonable.
Anticoagulation reversal protocols are well established for war-
farin and VKAs. Idarucizumab has been approved for reversing dabi-
gatran, and andexanet alfa has been developed for reversal of anti-Xa
agents. Data specific to reversal in CKD patients are limited.89
Antiplatelet therapy for stroke
prevention for atrial fibrillation in
chronic kidney disease
In a general, mostly non-CKD population, the AVERROES trial of as-
pirin vs. apixaban was stopped early due to a higher risk of stroke
with aspirin but with similar bleeding risk in both groups.90 However,
there is insufficient evidence to recommend single or dual antiplatelet
therapy for prevention of stroke/thromboembolism in AF among pa-
tients with CKD G4, G5, or G5D, even when OAC is considered un-
desirable. Similarly, these patients should not receive concomitant
antiplatelet therapy while taking anticoagulants, unless there is a spe-
cific secondary indication (e.g. recent coronary stent). The duration
of concomitant single or dual antiplatelet therapy in those receiving
anticoagulants needs to be minimized and individualized based on
clinical factors and type of stent.91
Left atrial appendage occlusion in
chronic kidney disease
The left atrial appendage (LAA) is believed to be the site of thrombus
formation for most AF-related cardio-embolic strokes. Circulatory
exclusion of the LAA represents a non-pharmacological, device-
based therapy for stroke prevention that could conceivably be an op-
tion in moderate to high stroke risk in CKD, particularly with contra-
indications to long-term OAC. Five-year data from two randomized
trials of the WatchmanVR LAA occlusion device demonstrated a re-
duction in stroke risk comparable to warfarin but with additional re-
duction in major bleeding.92 However, CKD prevalence or severity
was not reported and could have been under-represented. The ma-
jority of patients receiving the device in trials and in practice are con-
tinued on dual- or single-antiplatelet drug therapy, which may be
associated with higher bleeding risk in CKD. Moreover, enrolled sub-
jects were without contraindications and hence randomized. Registry
data of the Amplatzer Cardiac Plug, a similar device, has shown com-
parable procedural safety in CKD vs. normal kidney function.93 A
randomized trial of LAA occlusion vs. VKAs in CKD Stages 4 and 5
(CKD G4 and G5) is ongoing (https://clinicaltrials.gov/ct2/show/
NCT02039167; 13 February 2018).
Rate vs. rhythm control of atrial
fibrillation
Indications for a rhythm control strategy in CKD patients mirror
those in the general population. The major evidence-based indication
........................................................................... .......................................................................
....................................................................................................................................................................................................................
Table 3 Recommendations for discontinuation of direct oral anticoagulant prior to elective procedures, according to
the risk of bleeding of any specific procedure intervention (low vs. high risk procedures)
Dabigatran Apixaban–Edoxaban–Rivaroxaban
No important bleeding risk and/or adequate local haemostasis possible:
perform at trough level (i.e. 12 or 24h after last intake)
Low risk High risk Low risk High risk
CrCl >_ 80mL/min >_24h >_48h >_24h >_48h
CrCl 50–80mL/min 36h 72h >_24h >_48h
CrCl 30–50mL/mina 48h 96h >_24h >_48h
CrCl 15–30mL/mina No official indication No official indication 36 h 48h
CrCl<15mL/min No official indication for use
There is no need for bridging with LMWH/UFH
Bold values deviate from the common stopping rule of >_24h low risk, >_48h high risk. Low risk is defined as a low frequency of bleeding and/or minor impact of a bleeding.
High risk is defined as a high frequency of bleeding and/or important clinical impact. Adapted from Heidbuchel et al.4
CrCl, creatinine clearance; DOAC, direct oral anticoagulant; LMWH, low molecular weight heparin; UFH, unfractionated heparin.
aMany of these patients may be on the lower dose of dabigatran (110mg b.i.d.) or apixaban (2.5mg b.i.d.), or have to be on the lower dose of rivaroxaban (15mg OD) or edox-
aban (30 mg OD). Dabigatran 110 mg b.i.d. has not been approved for use by the US Food and Drug Administration.
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..for a rhythm-control strategy for AF is symptom reduction, although
many patients are asymptomatic.5,49 Older randomized trials have
demonstrated that rhythm and rate control strategies are equivalent
in terms of their effects on risks of heart failure, stroke, and sur-
vival.94–97 Retrospective analyses have suggested rhythm control
with ablation provides superior outcomes, but the evidence is lim-
ited. Regardless of which strategy is pursued, anticoagulation should
also be continued based on stroke risk (as indicated by the CHADS2
or CHA2DS2-VASc score), unless otherwise contraindicated.
Additional factors that may favour attempts at rhythm control in-
clude difficulty in achieving adequate rate control, younger patient
age, tachycardia-mediated cardiomyopathy, first episode of AF, AF
that is precipitated by an acute illness or surgery, and patient prefer-
ence (Figure 3).5,49 Haemodialysis patients with haemodynamic in-
stability due to AF during dialysis sessions may benefit from rhythm
control. The impact of its treatment on outcome is unknown.98
Patients without clear indications for a rhythm control strategy
should default to rate control. In the general population of patients
with permanent AF and preserved ejection fraction, lenient rate con-
trol (i.e. resting heart rate < 110 beats per minute) has been shown
to be equivalent to a strict rate control for a combined endpoint
including stroke, heart failure, death, and need for pacemaker or
implantable cardioverter-defibrillator (ICD).99
No RCTs have specifically compared rate vs. rhythm control or
strict vs. lenient rate control in patients with CKD or ESKD. In a post
hoc analysis of the GUSTO III trial, treatment with a rhythm or rate
control strategy did not significantly impact short- or long-term mor-
tality regardless of kidney disease status.100
Considerations about rate control
Special considerations in CKD include alterations in symptomatology
and a potentially increased propensity to develop tachycardia-
mediated cardiomyopathy, given the prevalence of structural heart
disease. Moreover, the pharmacokinetic and dialyzability of rate con-
trol agents in CKD need to be considered (Table 4). When the ven-
tricular rate cannot be controlled with medical therapies alone,
atrioventricular nodal ablation and pacemaker implantation can be
considered. However, the high rates of complications from transve-
nous devices in haemodialysis patients should enter into the decision-
Figure 3 Algorithm for decision-making about rate vs. rhythm control in chronic kidney disease. Especially since chronic kidney disease patients
show a lot of specific characteristics regarding history, comorbidities and personal preferences, in each patient an individualized decision should be
made. Many aspects should be taken into account: the duration of atrial fibrillation, the symptom severity, renal clearance (risk of toxicity, dialyzabil-
ity), and potential contraindications for antiarrhythmic drugs due to structural heart disease, which is very frequent in these patients (such as left ven-
tricular hypertrophy, reduced ejection fraction, obstructive coronary artery disease). Moreover, proarrhythmic effects (such as QT prolongation)
may be pronounced because of electrolyte imbalances in chronic kidney disease. The figure suggests an algorithm presenting the most relevant crite-
ria that should be incorporated into a multidisciplinary decision-making process, including the treating nephrologist, a heart rhythm specialist, and
eventually also physicians of other disciplines. Of note, regardless of which strategy is chosen, oral anticoagulation should always be administered in
early stages of chronic kidney disease and at least be considered in advanced stages of chronic kidney disease (see section on Stroke prevention and
oral anticoagulation). AF, atrial fibrillation; CKD, chronic kidney disease; EF, ejection fraction; eGFR, estimated glomerular filtration rate; HD, haemo-
dialysis; LA, left atrial; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy. Adapted in part from Kirchhof et al.5
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making process.107 Whether leadless pacemakers have a role in this
situation remains to be determined.
Considerations about rhythm control
Direct current cardioversion (DCCV) is the most commonly used
method of rhythm restoration in patients with persistent AF. The
success rate of DCCV been reported to be similar regardless of kid-
ney function.108 However, the risk of recurrence of AF increases as
eGFR decreases, although patients with mild-to-moderate CKD in
whom sinus rhythm is maintained may experience an improvement
in kidney function.109 Direct current cardioversion alone is generally
insufficient to maintain normal sinus rhythm, and long-term antiar-
rhythmic drugs or ablation are necessary for rhythm control.
The use of antiarrhythmic drugs for rhythm control is limited in pa-
tients with CKD because of issues with renal clearance and proar-
rhythmic risks in individuals with structural heart disease (Table 5).
Amiodarone, the antiarrhythmic drug most commonly used to treat
AF, does not appear to negatively affect survival, regardless of eGFR
function, even in ESKD.111 Whether CKD patients treated with amio-
darone are at higher risk for organ toxicity is unknown.
Catheter ablation is more effective than antiarrhythmic drugs
alone for maintenance of sinus rhythm. The safety and efficacy of AF
ablation in CKD was evaluated in 21 091 ablations, in which 1593
cases (7.6%) had CKD and 60 were on dialysis.112 Among patients se-
lected for AF ablation, those with and without CKD had similar rates
of post-procedural complications and subsequent AF hospitalization,
DCCV, and repeat ablation, although the patients with CKD were
more likely to be re-admitted for heart failure. A meta-analysis of
four studies of pulmonary vein isolation using radiofrequency ablation
in patients with CKD showed a nearly two-fold increased risk of AF
recurrence, possibly as a result of larger pre-ablation left atrial vol-
umes, which may serve as a marker for non-pulmonary vein triggers
of AF.113 In a study of CKD patients undergoing cryoballoon ablation,
patients with CKD G3 had significantly higher rates of AF recurrence
compared with those with CKD G1 and G2.114 No cases of contrast-
induced nephropathy were reported. In general, sinus rhythm main-
tenance via ablation is associated with improved eGFR, while ablation
failure is associated with eGFR decline.115
Atrial fibrillation ablation may potentially provide survival benefit in
the setting of reduced left ventricular ejection fraction (LVEF) and
heart failure. A randomized trial of catheter ablation compared to
usual care in AF and LVEF < 35% recently reported an improvement
in survival associated with ablation116,117 (https://clinicaltrials.gov/ct2/
show/NCT00643188; 13 February 2018).
In contrast to atrial fibrillation, radiofrequency ablation for rhythm
control of atrial flutter should be considered as first-line therapy in CKD
patients given the high success and low complication rates of ablation.
Patients with CKD are at higher risk of long-term AF following ablation
of atrial flutter and may require long-term monitoring to survey for AF
recurrences if a withdrawal of anticoagulation is being considered.118
Lifestyle modifications
Weight loss and exercise, can reduce the burden of AF in the
general population,119,120 as does treatment for obstructive sleep
apnoea.121,122 Patients on haemodialysis have a four-fold higher
risk of sleep-disordered breathing compared with control pa-
tients matched for age, gender, race, and body mass index.123,124
However, in a claims-based study of older patients in the USA,
....................................................................................................................................................................................................................
Table 4 Characteristics of antiarrhythmic drugs for rate control in chronic kidney disease
Drug Protein
binding
Elimination Dialyzable Dosing in CKD
Atenolol 5% Excreted unchanged in urine Yes Dose may need to be reduced
Propranolol >90% Hepatic metabolism No Serum creatinine may increase, but no dose adjust-
ment is needed
Bisoprolol 30% 50% excreted unchanged in urine No Dose may need to be reduced in advanced CKD
Metoprolol 12% Hepatic metabolism Yes No dosage reduction needed
Carvedilol 99% Mainly biliary and 16% urinary No Specific guidelines for dosage adjustments in renal
impairment are not available; it appears no
dosage adjustments are needed
Labetalol 50% Inactive metabolites excreted in urine
(5% unchanged) and bile
No Dose reduction recommended in the elderly
Verapamil 90% 70% is excreted in the urine and 16% in faeces No Dose reduction by 20–25% if CrCl < 10 mL/min,
not cleared by haemodialysis
Diltiazem 70–80% 2–4% unchanged drug excreted in the urine No Use with caution
Digoxin 20–30% Main route of elimination is renal (closely
correlated with the GFR) with 25–28% of
elimination by non-renal routes
No Dosage adaptation is required, monitoring of serum
digoxin levels
Modified from Potpara et al.101 and Weir et al.102
Metoprolol elimination data from Hoffman et al.103
Labetalol protein binding data from Drugbank.ca104 and dialyzability data from in vitro data by Daheb et al.105
All other dialyzability data from Frishman.106
CKD, chronic kidney disease; CrCl, creatinine clearance; GFR, glomerular filtration rate.
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sleep-disordered breathing in haemodialysis patients was not
associated with AF.125
Prevention of sudden cardiac
death
Incidence and aetiology of sudden
cardiac death in chronic kidney disease
and end-stage kidney disease populations
There is an increased risk of SCD in CKD (Supplementary material
online, Table S4).126–132 SCD accounts for 25–29% of all-cause
mortality in haemodialysis patients and around 30–35% of all-cause
mortality in patients initiating dialysis.133–139 Recent data indicate that
although all-cause mortality rates in haemodialysis patients have been
decreasing, the rates of SCD remain the same, indicative of an
increased proportion of patients dying from SCD.140 Risk of all-cause
mortality is substantially higher in dialysis (15–20% at 1 year) than in
heart failure or post-infarction patients (3–8% at 1 year).140–143 Annual
risk of SCD is higher in haemodialysis patients in comparison to other
patient populations (Figure 4): 5–7% in haemodialysis patients, 4% in
heart failure patients, and 1.5–2.7% in non-dialysis patients. The annual
rates in non-dialysis patients are comparable to that of post-infarction
patients.126,132,136,140,142–144 Nephrologists should be encouraged and
educated to discuss risks and potential treatment options with
patients, and enhance participation in clinical trials.
There is a significant gap of knowledge in the understanding of
electrical and haemodynamic mechanisms underlying SCD (Figure 5).
In a retrospective study of haemodialysis patients who were pre-
scribed a wearable cardioverter defibrillator, 80% of cardiac arrests
were recorded as ventricular tachyarrhythmias (ventricular tachycar-
dia or ventricular fibrillation) compared to 20% bradyarrhythmias.145
In a recent study with continuous electrocardiogram (ECG) monitor-
ing, bradyarrhythmias and asystole, rather than ventricular tachyar-
rhythmias, were important determinants of SCD in ESKD patients.146
The definitions of sudden death and SCD in ESKD patients need to
be refined. The unexpected nature of sudden death needs to be
Figure 4 Annual rates of sudden cardiac death. CKD, chronic kid-
ney disease; GP, general population.
....................................................................................................................................................................................................................
Table 5 Characteristics of antiarrhythmic drugs for maintaining sinus rhythm in chronic kidney disease
Drug Protein
binding
Elimination Dialyzable Dosing in CKD Special considerations
in CKD
Flecainide 40% 35% excreted unchanged in
urine
No Dose reduction if eGFR
<35 mL/min/1.73 m2
Do not use if significant
structural heart disease
present
Propafenone 95% 38-50% excreted in urine as
active metabolites (1%
unchanged)
No Careful monitoring recom-
mended (in hospital initi-
ation if advanced CKD)
Do not use if significant
structural heart disease
present
Amiodarone 99% No renal elimination No No dosage requirements; not
dialyzable; many drug-to-
drug interactions
Dronedarone 98% 6% excreted in urine Unlikely to be dialyzed No dosage adaptation
required in kidney failure
Do not use if EF <35% or re-
cent CHF
Dofetilide 60–70% 80% renally excreted, as un-
changed (80%) or inactive/
minimally active
metabolites
Unknown Initial dose individualized on
the basis of CrCl and sub-
sequent dosing based on
CrCl and QTc monitoring
Contraindicated for CrCl
<20 mL/min
Sotalol Not protein
bound
70% excreted unchanged in
urine
Yes—give maintenance
dose after
dialysis or supplement
with 80 mg after HD
A relative contraindication in
view of the risk of proar-
rhythmic effects; in rare
and selected cases—dose
to be halved or reduced to
one quarter in CKD
A relative contraindication in
view of the risk of proar-
rhythmic effects
CHF, congestive heart failure; CKD, chronic kidney disease; CrCl, creatinine clearance; EF, ejection fraction; eGFR, estimated glomerular filtration rate; HD, haemodialysis.
Modified from Potpara et al.101
Propafenone elimination data from Drugbank.ca.110
Dialyzability data from Frishman.106
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.. emphasized to avoid misclassifications. Supplementary material on-
line, Table S5 proposes definitions of sudden death, SCD, and aborted
cardiac arrest pertinent for ESKD patients.
Risk factors for sudden cardiac death in
chronic kidney disease and end-stage
kidney disease patients
The mechanisms of SCD in CKD and ESKD incorporate the long-
standing, pathophysiologic abnormalities that predispose to the
arrhythmogenic conditions and the triggering mechanisms which pre-
cipitate sudden cardiac arrhythmia (Figure 6).
The roles of myocardial ischaemia, electrolyte, and volume shifts
with haemodynamic instability, left ventricular hypertrophy, fibrosis
and dysfunction, as well as autonomic dysregulation and sympathetic
overactivity in the pathway leading to SCD, will all need to be further
evaluated.
Risk factors predisposing to SCD have been identified in ESKD pa-
tients (Supplementary material online, Table S6) and usually their
combinations contribute to SCD.136,147 Future studies need to deter-
mine whether SCD-specific risk factors could be recognized.7 Since it
is difficult to identify SCD-specific risk factors in patients without
ESKD, it might be that just cardiac death-specific risk factors will
Figure 5 Mechanisms of death in chronic kidney disease patients.
Figure 6 Potential predisposing factors of sudden cardiac death.
CHF, congestive heart failure; CKD-MBD, chronic kidney disease-
mineral and bone disorders; LV, left ventricular; LVH, left ventricular
hypertrophy.
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suffice to evaluate life-saving interventions in ESKD patients.148 The
primary focus should be on modifiable risk factors which could be
targets for intervention (Supplementary material online, Table S6).147
The role of modifiable biomarkers (defined as laboratory tests that
are measurable in blood, urine, or saliva) has been investigated in risk
stratification of CKD and ESKD but requires further studies.149
Troponins and brain natriuretic peptides could have an additive value
and should be further explored to assess their role in a comprehen-
sive risk assessment for SCD.150–153
There are very limited data regarding the prognostic significance of
incidentally detected arrhythmias in CKD and ESKD. Identification of
episodes of non-sustained ventricular tachycardia, frequent prema-
ture ventricular complexes, bradyarrhythmias and pauses may be
useful in identifying patients at risk of SCD.154 Ongoing and upcoming
studies with long-term ECG monitoring devices (implantable loop re-
corders or external ECG monitoring patches worn over a few days
to weeks) will provide data regarding incidence and prognostic signifi-
cance of these arrhythmias.
Syncope is yet another important and not infrequent event
observed in CKD and ESKD patients, but its prognostic significance is
uncertain.155 Transient loss of consciousness due to hypovolaemia or
hypotension should be classified as syncope and considered as such
for prognostication and treatment.
The role of defibrillator therapies for
primary and secondary prevention of
sudden cardiac death in end-stage kidney
disease
Data regarding secondary prevention ICD therapy indicate some
benefits but further studies are needed to assess longer-term risk vs.
benefit that account for competing risks of death.7,156,157 Primary
prevention ICD therapy is indicated in patients with LVEF <_ 35% al-
though data on benefits of primary prevention ICD therapy in pa-
tients with LVEF <_ 35% and advanced CKD are not encouraging,158
as compromised by competing morbidity and mortality and high risk
of complications. Patients with LVEF <_ 35% account for 10–15% of
dialysis patients,159,160 but no data exist for the majority of dialysis pa-
tients with LVEF > 35%. Available data seem to suggest that the bene-
fit of ICDs decreases with declining GFRs, in relationship to
competing risks of comorbidity and mortality and high risk of compli-
cations.129,161 Studies with subcutaneous defibrillators, which do not
have transvenous hardware, are needed since this approach might be
associated with fewer and less severe complications, such as infec-
tion.162 Wearable cardioverter defibrillators may provide protection
for a limited high-risk period.145 Further assessment of pacing devices
for bradyarrhythmias (including leadless pacemakers) is needed.146
Potassium homeostasis and
handling in chronic kidney disease
and dialysis
Electrolyte abnormalities and risk for
cardiovascular or arrhythmic events
Although definitive evidence for causality is lacking, both hyperkalaemia
and hypokalaemia have been associated with higher risk of all-cause and
cardiovascular mortality in patients with ESKD. In patients on haemo-
dialysis, when pre-dialysis serum potassium values (i.e. potassium values
on blood drawn at the start of the haemodialysis procedure, in keeping
with clinical practice) rise or fall away from 5 mEq/L, the risk for sudden
cardiac arrest increases.147 Among incident haemodialysis patients,
higher mortality and hospitalization rates have been documented to
occur immediately after the 2-day interdialytic interval.163,164 A contri-
buting factor may be larger fluid accumulation followed by excessive
ultrafiltration and abrupt fluctuations in serum potassium concentra-
tions (Supplementary material online, Figure S1).165 In contrast, hypoka-
laemia is more common in patients on peritoneal dialysis, and
hypokalaemia has been associated with increased risk of all-cause, car-
diovascular, and infectious mortality in this subgroup of patients.166
Treatment options for improving
potassium homeostasis
Treatments for hyperkalaemia include dietary restriction, correction
of acidosis, increasing distal sodium load, and loop diuretics, and in the
case of hypokalaemia, potassium-sparing diuretics and potassium sup-
plements could be used.167 It may be possible to reduce the dose or
stop drugs that interfere with potassium homeostasis, such as nonster-
oidal anti-inflammatory drugs, sulfamethoxazole-trimethoprim, calci-
neurin inhibitors, and non-selective beta blockers. Pharmacologic
treatments for managing hyperkalaemia include the cation-exchange
resin kayaexalate,168 calcium-resin resonium,169 the potassium-binding
polymer patiromer,170 and the potassium trap ZS-9.167 Beyond the
treatment of hyperkalaemia, these agents might also enable more
patients with concomitant CKD to be started on or maintained
on guideline-recommended renin–angiotensin–aldosterone system
(RAAS) inhibitors, and this possibility is currently being investigated.167
In addition to reducing serum potassium, patiromer has been shown
to reduce serum aldosterone levels in patients with CKD and hyper-
kalaemia taking RAAS inhibitors.171 Other important questions re-
garding potassium binders relate to their safety and efficacy in post-
kidney transplant patients, patients with Type IV renal tubular acidosis,
or patients taking calcineurin inhibitors.
Data from three clinical trials have indicated that dual RAAS block-
ade therapy increases the risk of hyperkalaemia in patients with
CKD.172–174 Meta-analysis data have indicated that mineralocortic-
oids can mediate hyperkalaemia in patients undergoing dialysis, but
large trials are needed to better evaluate this process and its clinical
significance.175 In patients with Type 2 diabetes, a sodium-glucose
cotransporter 2 (SGLT2) inhibitor has been associated with small
mean changes in serum electrolytes and less hyperkalaemia com-
pared to placebo, especially in patients taking anti-hypertensives that
interfere with potassium excretion.176
Dialysate and dialysis parameters
For patients undergoing haemodialysis, both the potassium concentra-
tion in the dialysate and the schedule of haemodialysis treatments af-
fect the risk of sudden death (Figure 6). Potential confounding factors,
such as nutrition, treatment compliance, and comorbidities, have not
been thoroughly evaluated. It is also not clear whether or how much
central venous pressure, hypervolemia, and pulmonary hypertension
predispose patients to arrhythmic events. Three studies have indicated
that a low potassium dialysate concentration (<2 mEq/L) is associated
10 M.P. Turakhia et al.
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with a higher incidence of sudden death, especially when pre-dialysis
patient serum levels are <5 mEq/L.147,177,178 For patients with a pre-
dialysis serum potassium concentration of >5 mEq/L, the risks associ-
ated with low potassium dialysates have not been statistically signifi-
cant. In Dialysis Outcomes and Practice Patterns Study (DOPPS),
mortality rates were similar in patients prescribed 2 and 3 mEq/L
dialysate.179 Rapid correction of acidaemia, low serum or dialysate
calcium, and high ultrafiltration rates may contribute to the
arrhythmogenic potential of low potassium dialysate.147,180 In a study
of 50 patients undergoing thrice-weekly dialysis, risk of SCD and sig-
nificant arrhythmias was greater during the 72-h vs. 48-h breaks.
There were no analyses specifically related to potassium levels in these
studies.146 Whether shortening the interval between haemodialysis
sessions could result in clinically significant reductions in sudden car-
diac arrest and its relationship to potassium levels is not clear and war-
rants further study. Dialysate concentrations of bicarbonate, calcium,
magnesium, and glutamic acid also are likely to be relevant to risk for
arrhythmic events. It is possible that personalizing dialysis parameters
Table 6 Arrhythmias and chronic kidney disease: current knowledge gaps and future research recommendations
• Should AF be a required secondary endpoint in future cardiovascular clinical trials among CKD patients? This will enable future studies to examine the
contribution of AF to various outcomes (e.g. cognitive impairment).
• Can we improve upon risk assessment in patients with CKD/CKD G5D by examining unique risk factors for stroke (e.g. proteinuria) and bleeding (e.g.
proteinuria, platelet dysfunction, vascular access, dialysis anticoagulation)?
• Based on a review of large observational studies, can we ascertain the combinations of risk factors that predict competing SCD vs. non-SCD and car-
diac vs. non-cardiac death endpoints in patients with CKD/CKD G5D?
• Are there modifiable risk factors (e.g. long chain omega-3 fatty acids) or pharmacological therapies for SCD worth investigating?
• What is the incidence and prognostic significance of syncope in dialysis patients (on conventional or novel modalities) and transient hypotension, hypo-
volemia, and bradycardia during and outside dialysis sessions?
• Is there a role for biomarkers (e.g. troponins, BNP) and markers of autonomic dysregulation and sympathetic overactivity in predicting cardiac death
and SCD? Is there prognostic significance in incidentally detected arrhythmias?
• Among patients on dialysis, can we use modern imaging techniques (e.g. cardiac magnetic resonance imaging with T1 mapping and speckle tracking
imaging echocardiography both during haemodialysis and on a non-dialysis day), long-term ECG monitoring, and emerging biomarkers to ascertain pre-
disposing factors to SCD?
• Since patients with CKD G5D have consistently lower time in TTR values (despite comparable intensity of monitoring) that may contribute to higher
risk of bleeding, what is the evidence regarding the role of TTR in decision-making and transitioning to DOAC therapy with suboptimal TTR?
• Estimates of kidney function using eGFR and eCrCl are not equivalent and can lead to important dose discrepancies with DOACs. Both the conference
participants and ESC advocate the use of eGFR (over eCrCl) in future trials because of established superiority in estimating kidney function and to rec-
oncile the measure used in pragmatic clinical practice. For adoption of this measure in future trials however, we recognize that there would be need
for upfront endorsement of eGFR as the preferred measure for estimating kidney function by regulatory agencies.
• Should serial measurements of kidney function be considered to determine if anticoagulation (e.g. DOACs) is associated with changes in kidney
function?
• Does heparin use during haemodialysis alter the risk–benefit ratio when used with concomitant oral anticoagulation? Are there clinical efficacy or
safety data evaluating whether the use of erythropoietin therapy influences stroke reduction with anticoagulant therapy?
• Is there utility in employing left atrial appendage occluder devices in patients with CKD G5D who are already at high risk of bleeding and endovascular
infections?
• What is the role of DOACs among kidney transplant patients? Do specific drug–drug interactions favour certain agents over others?
• Is ICD therapy efficacious in the primary and secondary prevention of SCD in ESKD? If so, what are the risk–benefit ratios? Utility of leadless pace-
makers? Additional studies examining transvenous, subcutaneous, and wearable defibrillators are needed in CKD patients with EF >35% since they ac-
count for 90% of ESKD patients.
• What are the long-term outcomes of rate vs. rhythm control in CKD or dialysis patients? What should guide the selection of rate vs. rhythm control in
this patient population? For the former, what is the optimal rate control and what are the preferred rate-controlling agents? Utility of transvenous vs.
leadless permanent pacemaker following AV node ablation? For rhythm control, what is benefit–risk ratio for ablation vs. antiarrhythmic drugs?
• What is the ideal ablation approach? For antiarrhythmic drugs, are there comparative trials to provide information on safety, pharmacokinetics and effi-
cacy on various agents (especially amiodarone)? Is there a long-term need for oral anticoagulation in patients with successful rhythm control?
• Does personalizing dialysis prescription (e.g. electrolyte dialysate, close monitoring of potassium levels or volume management) reduce the risk for
SCD? Do changes in other electrolytes associated with arrhythmic predisposition in haemodialysis patients (such as magnesium) affect clinical
outcomes?
AF, atrial fibrillation; AV, atrioventricular; BNP, B-type natriuretic peptide; CKD, chronic kidney disease; DOAC, direct oral anticoagulant; ECG, electrocardiogram; eCrCl, esti-
mated creatinine clearance; EF, ejection fraction; eGFR, estimated glomerular filtration rate; ESC, European Society of Cardiology; ESKD, end-stage kidney disease; G5D, CKD
stage G5 patients on dialysis therapy; ICD, implantable cardioverter-defibrillator; SCD, sudden cardiac death; TTR, time in therapeutic range.
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for individual patients could reduce risk of SCD, but this is untested
and would be logistically complicated to implement.
Fluid control during dialysis
Ultrafiltration rates higher than 10 mL/h/kg have been associated
with a higher likelihood of intradialytic hypotension and risk of mor-
tality.181 Haemodynamic stress during dialysis induces cardiac stun-
ning, which over time may progress to the development of regional
fixed systolic dysfunction, consistent with underlying myocardial hi-
bernation and fibrosis.182 A retrospective analysis has indicated that
greater interdialytic weight gain is associated with an increased risk of
cardiovascular morbid events183; therefore, strategies that mitigate
interdialytic weight gain warrant investigation.
Conclusion
People with CKD have an increased burden from AF relative to those
without CKD, and an elevated risk of stroke. For preventing stroke in
patients with eCrCl 30–50 mL/min, DOACs are non-inferior to war-
farin and have a more favourable safety profile. For CKD G5D pa-
tients with AF, there are insufficient clinical efficacy and safety data to
routinely recommend VKA treatment for preventing stroke.
Evidence from older randomized trials indicates that pharmaco-
logical rhythm and rate control strategies are equivalent in terms of
their efficacy on risks of heart failure, stroke, and survival. However,
catheter ablation, which is superior to antiarrhythmic drug therapy
for freedom from AF recurrence, has comparable safety in CKD and
non-CKD. The role of AF ablation may continue to evolve, particu-
larly among other co-morbid conditions such as heart failure.
Regardless of whether a rhythm or rate strategy is pursued, anticoa-
gulation should also be prescribed unless otherwise contraindicated
based on stroke risk.
The risk for SCD is increased in patients with CKD, and for those
with ESKD on dialysis, several factors that increase risk have been
identified. Studies are needed to identify risk factors for SCD in CKD
non-dialysis patients. For preventing SCD in ESKD, primary preven-
tion ICD therapy is indicated in patients with LVEF <_ 35%, although
data on its benefits in these patients are not encouraging. Data re-
garding secondary prevention ICD therapy indicate some benefits,
but further studies are needed to assess long-term risk–benefit ratios
in these patients. Available data seem to suggest that the benefit of
ICDs decreases with declining GFR.
For patients undergoing haemodialysis, both the potassium con-
centration in the dialysate and the schedule of haemodialysis treat-
ments affect the risk of sudden death. Whether shortening the
interval between haemodialysis sessions could result in clinically sig-
nificant reductions in sudden cardiac arrest is not yet clear and war-
rants further study. It is possible that personalizing dialysis
parameters for individual patients could reduce risk of SCD, but this
is untested and would be logistically complicated to implement.
Recent guidelines include considerable practical and scientific
detail on management of these arrhythmias in CKD.3–7,85,184
However, there remain substantial evidence gaps, which will re-
quire clinical trials, and when not possible, robust observational
data. We have outlined research recommendations in the hopes
that future investigations can better advance the evidence base in
this area (Table 6). A multidisciplinary approach is vital for
understanding the mechanisms of arrhythmias in CKD as well as
for evaluating therapies and improving clinical care. Nephrologists
and cardiologists should initiate and continue partnerships in de-
signing and conducting clinical trials as well as treating individual
patients with CKD and AF.
Supplementary material
Supplementary material is available at European Heart Journal online.
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